128 related articles for article (PubMed ID: 19569219)
21. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
22. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
23. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
[TBL] [Abstract][Full Text] [Related]
24. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
[TBL] [Abstract][Full Text] [Related]
25. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
[TBL] [Abstract][Full Text] [Related]
26. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
Prasad B; Lai Y; Lin Y; Unadkat JD
J Pharm Sci; 2013 Mar; 102(3):787-93. PubMed ID: 23280364
[TBL] [Abstract][Full Text] [Related]
27. Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
Kim KA; Cha YJ; Lee HM; Joo HJ; Park JY
Clin Chim Acta; 2015 Jan; 438():7-11. PubMed ID: 25124867
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
29. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.
Kusuhara H; Furuie H; Inano A; Sunagawa A; Yamada S; Wu C; Fukizawa S; Morimoto N; Ieiri I; Morishita M; Sumita K; Mayahara H; Fujita T; Maeda K; Sugiyama Y
Br J Pharmacol; 2012 Jul; 166(6):1793-803. PubMed ID: 22300367
[TBL] [Abstract][Full Text] [Related]
31. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
[TBL] [Abstract][Full Text] [Related]
32. Association between the ABCG2 C421A polymorphism and Alzheimer's disease.
Fehér Á; Juhász A; László A; Pákáski M; Kálmán J; Janka Z
Neurosci Lett; 2013 Aug; 550():51-4. PubMed ID: 23827224
[TBL] [Abstract][Full Text] [Related]
33. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.
Futatsugi A; Toshimoto K; Yoshikado T; Sugiyama Y; Kato Y
Drug Metab Dispos; 2018 May; 46(5):749-757. PubMed ID: 29440178
[TBL] [Abstract][Full Text] [Related]
35. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
36. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
37. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
38. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
39. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
40. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]